NASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis $41.26 -2.45 (-5.61%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$41.23▼$45.0050-Day Range$35.29▼$47.7252-Week Range$5.65▼$65.60Volume874,719 shsAverage Volume724,581 shsMarket Capitalization$2.14 billionP/E RatioN/ADividend YieldN/APrice Target$66.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Janux Therapeutics alerts: Email Address Janux Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside60.3% Upside$66.13 Price TargetShort InterestHealthy8.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.17) to ($1.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.19 out of 5 starsMedical Sector286th out of 910 stocksPharmaceutical Preparations Industry122nd out of 426 stocks 4.4 Analyst's Opinion Consensus RatingJanux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageJanux Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Janux Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.58% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Janux Therapeutics has recently decreased by 11.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JANX. Previous Next 2.0 News and Social Media Coverage News SentimentJanux Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Janux Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Janux Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.17) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -33.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -33.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Janux Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About Janux Therapeutics Stock (NASDAQ:JANX)Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Read More JANX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JANX Stock News HeadlinesSeptember 6 at 5:33 PM | benzinga.comNavigating 5 Analyst Ratings For Janux TherapeuticsSeptember 6 at 12:32 PM | seekingalpha.comJanux initiated at Stifel with Buy on upcoming data updateSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 1, 2024 | finance.yahoo.comJanux Therapeutics, Inc. (JANX)September 1, 2024 | seekingalpha.comJanux Therapeutics: Buoyed By Buyout SpeculationSeptember 1, 2024 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Trading Up 5.3%August 9, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)August 8, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)September 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 7, 2024 | finance.yahoo.comJanux Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsJuly 22, 2024 | businesswire.comJanux Therapeutics Announces Updates to Board of DirectorsJuly 20, 2024 | investing.comJanux Therapeutics Inc (JANX)June 26, 2024 | seekingalpha.comJanux Therapeutics: Promising T-Cell Engager Platform In Cancer TherapyMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)May 13, 2024 | markets.businessinsider.comAnalyst Ratings For Janux TherapeuticsMay 8, 2024 | benzinga.comJanux Therapeutics Options Trading: A Deep Dive into Market SentimentMay 8, 2024 | finance.yahoo.comJanux Therapeutics Reports Narrower Q1 Loss, Misses Revenue EstimatesMay 7, 2024 | businesswire.comJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsSee More Headlines Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JANX CUSIPN/A CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$66.13 High Stock Price Target$100.00 Low Stock Price Target$42.00 Potential Upside/Downside+60.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,290,000.00 Net Margins-291.17% Pretax Margin-291.17% Return on Equity-8.78% Return on Assets-8.20% Debt Debt-to-Equity RatioN/A Current Ratio57.34 Quick Ratio57.34 Sales & Book Value Annual Sales$15.13 million Price / Sales141.43 Cash FlowN/A Price / Cash FlowN/A Book Value$12.61 per share Price / Book3.27Miscellaneous Outstanding Shares51,851,000Free Float33,496,000Market Cap$2.14 billion OptionableOptionable Beta3.57 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. David Alan Campbell Ph.D. (Age 64)President, CEO & Director Comp: $1.04MMr. Charles M. Winter (Age 55)Chief Technical Officer Comp: $590.4kMr. Byron Robinson J.D. (Age 59)Ph.D., Chief Strategy Officer Comp: $723kMr. Tighe M. Reardon C.F.A. (Age 48)CPA, Acting Chief Financial Officer Dr. Tommy Diraimondo Ph.D. (Age 38)Chief Scientific Officer Mr. James PenningtonGeneral CounselMs. Brenda Van VreeswykHead of Human ResourcesMr. Andy Hollman Meyer (Age 40)Chief Business Officer More ExecutivesKey CompetitorsDICE TherapeuticsNASDAQ:DICEPandion TherapeuticsNASDAQ:PANDPraxis Precision MedicinesNASDAQ:PRAXScholar RockNASDAQ:SRRKIGM BiosciencesNASDAQ:IGMSView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 136,430 shares on 8/19/2024Ownership: 0.263%Blue Owl Capital Holdings LPBought 40,000 shares on 8/15/2024Ownership: 0.077%The Manufacturers Life Insurance Company Bought 16,864 shares on 8/15/2024Ownership: 0.046%AQR Capital Management LLCBought 5,125 shares on 8/15/2024Ownership: 0.010%ProShare Advisors LLCSold 1,137 shares on 8/14/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions JANX Stock Analysis - Frequently Asked Questions How have JANX shares performed this year? Janux Therapeutics' stock was trading at $10.73 at the beginning of 2024. Since then, JANX stock has increased by 284.5% and is now trading at $41.26. View the best growth stocks for 2024 here. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) issued its earnings results on Wednesday, August, 7th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.20. The company's revenue for the quarter was up 709.1% compared to the same quarter last year. When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $152 million in an IPO on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. Who are Janux Therapeutics' major shareholders? Top institutional investors of Janux Therapeutics include Logos Global Management LP (1.45%), Samlyn Capital LLC (0.63%), Point72 Asset Management L.P. (0.26%) and Ensign Peak Advisors Inc (0.26%). Insiders that own company stock include Ra Capital Management, LP, Ventures Xi LP Avalon and Tighe Reardon. View institutional ownership trends. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JANX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
